ArticleJournal of clinical medicine2024
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study.
Abstract read
In one paragraph
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.Advances in therapy · 2026Article
- Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry.United European gastroenterology journal · 2026Observational
- Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective.Intestinal research · 2026Review
- Filgotinib Is an Effective and Safe Treatment Option for Difficult-To-Treat Ulcerative Colitis: Real-World Evidence of the Dutch Initiative on Crohn and Colitis (ICC) Registry.United European gastroenterology journal · 2026Article
- Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications.Clinical and experimental gastroenterology · 2026Article
- Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.Journal of clinical medicine · 2025Article
- Induction Efficacy and Safety of Upadacitinib for Active Crohn's Disease in Japanese Patients: A Multicenter Retrospective Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- JAK Inhibitor and Crohn's Disease.Biomedicines · 2025Review
- Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives.Biomedicines · 2025Review
- Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Neuroinflammation is responsible for pain in endometriosis - targeting the JAK-STAT pathway and mast cell activation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Bernadett FarkasCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.ORCID 0009-0007-8816-0138
Talat BessissowDivision of Gastroenterology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.
Jimmy K LimdiNorthern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK.
Karishma Sethi-AroraNorthern Care Alliance NHS Foundation Trust, Manchester M6 8HD, UK.
Anna KagramanovaMoscow Clinical Scientific Center Named after A. S. Loginov, Moscow 111123, Russia.ORCID 0000-0002-3818-6205
Oleg KnyazevMoscow Clinical Scientific Center Named after A. S. Loginov, Moscow 111123, Russia.
Cristina BezzioIBD Center, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.
Alessandro ArmuzziIBD Center, IRCCS Humanitas Research Hospital, 20089 Milan, Italy.ORCID 0000-0003-1572-0118
Milan LukasClinical and Research Centre for Inflammatory Bowel Diseases, 19000 Prague, Czech Republic.
George MichalopoulosGeneral Hospital of Athens "G. Gennimatas", 11527 Athens, Greece.
Elena ChaskovaDepartment of Coloproctology, Irkutsk Regional Hospital, Irkutsk 664528, Russia.
Edoardo Vincenzo SavarinoGastroenterology Unit, Azienda Ospedale Università of Padua, 35128 Padua, Italy.ORCID 0000-0002-3187-2894
Fabiana CastiglioneGastroenterology Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
Antonio RispoGastroenterology Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.ORCID 0000-0002-1454-2412
Eszter SchäferDepartment of Gastroenterology, Hungarian Defence Forces Military Hospital, 1062 Budapest, Hungary.
Simone SaibeniGastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Milan, Italy.ORCID 0000-0001-5677-2534
Rafal FilipDepartment of Gastroenterology with IBD Unit, Clinical Hospital 2, 35301 Rzeszów, Poland.ORCID 0000-0002-5954-151X
Mohamed AttauabiDepartment of Gastroenterology and Hepatology, Copenhagen University Hospital-Herlev and Gentofte, 2730 Herlev, Denmark.ORCID 0000-0003-0323-7030
Fotios S FousekisDivision of Gastroenterology, University Hospital of Ioannina, 45500 Ioannina, Greece.
Péter BacsurCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.ORCID 0000-0002-8534-0068
Tamás ResálDepartment of Gastroenterology, Hungarian Defence Forces Military Hospital, 1062 Budapest, Hungary.
Anita BálintCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Emese IványCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Zoltán SzepesCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Zsófia BőszeCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Anna FábiánCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Renáta BorCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Klaudia FarkasCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Peter L LakatosDivision of Gastroenterology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0002-3948-6488
Tamás MolnárCenter for Gastroenterology, University of Szeged, 6725 Szeged, Hungary.
Funding
EU's Horizon 2020 research and innovation program 739593Janos Bolyai Research Grant BO/00598/19/5National Research, Development and Innovation Fund TKP2021-EGA-28National Research, Development and Innovation Office FK134863; K143549New National Excellence Programme UNKP-23-3-SZTE-268
Abstract
PubMed holds no abstract for this paper.
Indexed as
Crohn’s diseasefilgotinibJAK-inhibitorsulcerative colitisupadacitinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.